AbbVie Inc (ABBV)vsAvadel Pharmaceuticals PLC (AVDL)
ABBV
AbbVie Inc
$291.27
+1.07%
HEALTHCARE · Cap: $521.11B
AVDL
Avadel Pharmaceuticals PLC
$21.64
0.00%
HEALTHCARE · Cap: $2.12B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 26463% more annual revenue ($66.01B vs $248.52M). ABBV leads profitability with a 15.7% profit margin vs -0.0%. AVDL appears more attractively valued with a PEG of 0.07. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
AVDL
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-85.2%
Fair Value
$157.29
Current Price
$291.27
$133.98 premium
Margin of Safety
+69.2%
Fair Value
$70.24
Current Price
$21.64
$48.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.5% revenue growth
0.0% earnings growth
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : AVDL
The strongest argument for AVDL centers on PEG Ratio. PEG of 0.07 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : AVDL
The primary concerns for AVDL are Revenue Growth, EPS Growth, Operating Margin.
Key Dynamics to Monitor
ABBV profiles as a mature stock while AVDL is a turnaround play — different risk/reward profiles.
AVDL carries more volatility with a beta of 1.63 — expect wider price swings.
ABBV is growing revenue faster at 10.3% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 41/100), backed by strong 15.7% margins and 10.3% revenue growth. AVDL offers better value entry with a 69.2% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Avadel Pharmaceuticals PLC
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Avadel Pharmaceuticals plc is a biopharmaceutical company in the United States. The company is headquartered in Dublin, Ireland.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?